Biotechnology company Illumina, Inc. (NASDAQ: ILMN) on Wednesday announced financial results for the second quarter of 2023.
- Second-quarter revenue came in at $1.18 billion, up 1% from Q2 2022; a 3% increase on a constant currency basis
- Net loss per share was $1.48 in Q2, compared to a loss per share of $3.40 in the year-ago quarter
- On an adjusted basis, it was earnings of $0.32 per share for Q2 2023, compared to $0.57 per share last year
- The company expects fiscal year 2023 consolidated revenue growth of approximately 1%
- It is looking for a loss in the range of $2.08 per share to $1.93 per share for fiscal 2023
- Full-year adjusted earnings per share is expected to be in the range of $0.75 to $0.90
Most Popular
AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts' expectations. Adjusted
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases. In an email interview with AlphaStreet, CEO Dr.
Lamb Weston (LW) is set to report Q2 2026 earnings next week, here’s what to look for
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose over 1% on Thursday. The stock has gained 4% over the past three months. The French fry giant is slated to
